TheraCell Inc., a leading allograft solution company’s newest procedure-specific fiber graft form, the TheraFuze DBF Fiber Bag, is available for use in spinal and orthopedic surgeries, including minimally invasive procedures.
The TheraFuze DBF Fiber Bag is a 100% allograft tissue alternative to resorbable polymer mesh bag products. The Fiber Bag is made from cortical demineralized bone fibers and processed using TheraCell’s proprietary Bone Textile technology. TheraCell’s patented TheraFuze DBF processes have been developed to produce uniform fiber geometry, size, and texture to preserve the natural collagen structure of the allograft. TheraCell’s FiberLok technology allows the Fiber Bag products to maintain their form and integrity after rehydration, permitting adequate time for manipulation and implantation.
This next-generation posterolateral solution is designed to be an improved alternative to the traditional boat, offering complete containment of added graft material. The Fiber Bag may be packed with autograft or additional allograft material, and the open end of the bag can be sutured for closure following rehydration. The fully contained fiber bag construct may be placed in the posterolateral gutters, in a bone void or cavity, or may be delivered using minimally invasive techniques.
Nelson Scarborough, Ph.D., Chief Scientific Officer and Co-Inventor on the Fiber Bag patent, TheraCell, said: “The versatility of our technology platform allowed us to develop and commercialize a range of procedure-specific fiber graft forms to rapidly expand our portfolio of TheraFuze DBF Fiber products, and the issuance of this new patent further enhances our strong portfolio of intellectual property and demonstrates our ongoing commitment to innovation, and leadership in the orthopedic allograft industry.”
